Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis

Trial Profile

A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2019

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTRAEA; PsA-II
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Jun 2019 Results (n=398) assessing safety of abatacept treatment over 2 years in patients with psoriatic arthritis, presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 24 Oct 2018 Results of post hoc analysis evaluating the efficacy of Abatacept in patients not receiving Methotrexate, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top